Calliditas Therapeutics AB (publ) (CALT) Earnings Date, Estimates & Call Transcripts $40.00 0.00 (0.00%) As of 04/14/2025 Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock Calliditas Therapeutics AB (publ) Earnings Summary Latest Q2 Earnings DateAug. 13EstimatedConsensus EPS (Aug. 13) -$0.25 Actual EPS (Aug. 13) -$0.16 Beat By $0.09 Actual Revenue (Aug. 13) $52.36MCalliditas Therapeutics AB (publ) released Q2 2024 earnings on August 13, 2024, reporting an EPS of -$0.16, which topped analysts' consensus estimates of -$0.25 by $0.09. Quarterly revenue was reported to be $52.36 million, above analyst estimates of $42.89 million. With a trailing EPS of -$1.85, Calliditas Therapeutics AB (publ)'s earnings are expected to grow next year, from ($0.99) to $4.61 per share. Q2 2024 Earnings ResourcesQ2 2024 Earnings ReportConference Call Transcript & Audio Interim Report Slide DeckSlide DeckFull Screen Slide DeckPowered by Get Calliditas Therapeutics AB (publ) Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Calliditas Therapeutics AB (publ) and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCALT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CALT Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Calliditas Therapeutics AB (publ) Analyst EPS EstimatesCurrent Year EPS Consensus Estimate ($0.99) EPSNext Year EPS Consensus Estimate $4.61 EPS Remove Ads Calliditas Therapeutics AB (publ) Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/13/2024Q2 2024-$0.25-$0.16+$0.09-$0.16$42.89M$52.36M5/23/2024Q1 2024-$0.14-$0.88 -$0.74-$0.88$35.78M$28.43M2/21/2024Q4 2023-$0.09-$0.07+$0.02-$0.06$36.24M$42.45M11/7/2023Q3 2023-$0.22-$0.58 -$0.36-$0.58$28.09M$27.25M8/17/2023Q2 2023-$0.25-$0.33 -$0.08-$0.33$28.34M$25.60M5/16/2023Q1 2023-$0.57-$0.67 -$0.10-$0.67$19.05M$18.32M Calliditas Therapeutics AB (publ) Earnings - Frequently Asked Questions When did Calliditas Therapeutics AB (publ) announce their last quarterly earnings? Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last announced its quarterly earning data on Tuesday, August 13, 2024. Learn more on CALT's earnings history. Did Calliditas Therapeutics AB (publ) beat their earnings estimates last quarter? In the previous quarter, Calliditas Therapeutics AB (publ) (NASDAQ:CALT) reported ($0.16) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.25) by $0.09. Learn more on analysts' earnings estimate vs. CALT's actual earnings. How can I listen to Calliditas Therapeutics AB (publ)'s earnings conference call? The conference call for Calliditas Therapeutics AB (publ)'s latest earnings report can be listened to online. Listen to Conference Call How can I read Calliditas Therapeutics AB (publ)'s conference call transcript? The conference call transcript for Calliditas Therapeutics AB (publ)'s latest earnings report can be read online. Read Transcript How much revenue does Calliditas Therapeutics AB (publ) generate each year? Calliditas Therapeutics AB (publ) (NASDAQ:CALT) has a recorded annual revenue of $1.60 billion. How much profit does Calliditas Therapeutics AB (publ) generate each year? Calliditas Therapeutics AB (publ) (NASDAQ:CALT) has a recorded net income of -$43.96 million. CALT has generated -$1.85 earnings per share over the last four quarters. What is Calliditas Therapeutics AB (publ)'s EPS forecast for next year? Calliditas Therapeutics AB (publ)'s earnings are expected to grow from ($0.99) per share to $4.61 per share in the next year. More Earnings Resources from MarketBeat Related Companies NUVL Earnings Results GRFS Earnings Results ELAN Earnings Results VRNA Earnings Results ADMA Earnings Results CYTK Earnings Results PCVX Earnings Results RYTM Earnings Results PTCT Earnings Results OGN Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside? Remove Ads This page (NASDAQ:CALT) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CALT Stock Free CALT Stock Alerts